Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1646973 | 0.89 | ALDH1A1 (0.41) | ALDH1A1KDM4ETSHRSMN1; SMN2MAPT | |
| SCHEMBL3635793 | 0.87 | ALDH1A1 (0.47) | ALDH1A1KDM4ETSHRSMN1; SMN2MAPT | |
| SCHEMBL11744524 | 0.81 | ALDH1A1 (0.44) | ALDH1A1KDM4ETSHRSMN1; SMN2MAPT | |
| SCHEMBL11522426 | 0.81 | RORC (0.49) | ALDH1A1KDM4ESMN1; SMN2MAPTKMT2A | |
| SCHEMBL4639251 | 0.80 | TSHR (0.40) | ALDH1A1KDM4ETSHRSMN1; SMN2MAPT | |
| SCHEMBL28300921 | 0.78 | TSHR (0.53) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL5875056 | 0.77 | KMT2A (0.47) | ALDH1A1KDM4ETSHRSMN1; SMN2MAPT | |
| SCHEMBL29561089 | 0.76 | TSHR (0.51) | ALDH1A1TSHRSMN1; SMN2MAPTPKM | |
| SCHEMBL1355836 | 0.76 | TSHR (0.51) | ALDH1A1TSHRSMN1; SMN2MAPTPKM | |
| SCHEMBL28088184 | 0.76 | MAPT (0.45) | ALDH1A1KDM4ETSHRSMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3508204-B1 | QUINAZOLIN-8-YL DERIVATIVES FOR USE IN METHODS OF TREATING MELANOMA, NON-SMALL CELL LUNG CANCER, THYROID CANCER, OVARIAN CANCER, OR COLON CANCER | NEUPHARMA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC | 2024-06-20 | — | — | US | disclosed |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | ARAXES PHARMA LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2022-11-10 | — | — | US | disclosed |
| CN-109851617-B | Chemical entities, compositions, and methods | 润新生物公司 | 2022-08-16 | — | — | CN | disclosed |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-7304084-B2 | 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2007-12-04 | — | — | US | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125405-A2 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007076092-A2 | NITROGEN- CONTAINING BICYCLIC HETROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20060122248-A1 | Methods of making 6-[(4,5-dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2006-06-08 | — | — | US | disclosed |
| EP-1594862-A1 | METHODS OF MAKING 6- (4,5-DIHYDRO-1H-IMIDAZOL-2-YL)AMINO-&rs qb;-7-METHYL-1H-BENZIMIDAZOLE-4-CARBONITRILE AND ITS PREFERRED SALT FORM | The Board of Regents of the University of Nebraska (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004074279-A1 | METHODS OF MAKING 6-[(4,5-DIHYDRO-1H-IMIDAZOL-2-YL)AMINO-]-7-METHYL-1H-BENZIMIDAZOLE-4-CARBONITRILE AND ITS PREFERRED SALT FORM | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167194-A1 | Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167194-A1 | Methods of making 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | AGTR2, ALDH1A2, REN | ALDH1A1 196/4885KDM4E 1459/4885TSHR 4384/4885 |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | BRAF, NRAS, RAF1 | ALDH1A1 2020/4885KDM4E 1653/4885TSHR 1037/4885 |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | ALDH1A1 3691/4885KDM4E 963/4885TSHR 4017/4885 |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | ALDH1A1 3691/4885KDM4E 963/4885TSHR 4017/4885 |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | ALDH1A1 3691/4885KDM4E 963/4885TSHR 4017/4885 |
| US-20230203018-A1 | COVALENT INHIBITORS OF KRAS | KRAS, NRAS, HRAS | ALDH1A1 1640/4885KDM4E 2066/4885TSHR 2016/4885 |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | ALDH1A1 3691/4885KDM4E 963/4885TSHR 4017/4885 |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | ALDH1A1 3691/4885KDM4E 963/4885TSHR 4017/4885 |
| US-20060122248-A1 | Methods of making 6-[(4,5-dihydro-1H-imidazol-2-yl)amino-]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt form | AGTR2, ALDH1A2, REN | ALDH1A1 119/4885KDM4E 1460/4885TSHR 4497/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | ALDH1A1 3080/4885KDM4E 1359/4885TSHR 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.